High Flow Nasal Cannula for Lung Cancer

This trial tests whether a high flow nasal cannula can make certain lung procedures smoother and quicker. The focus is on reducing interruptions and breathing issues during a specific lung cancer procedure. Participants will receive oxygen through either a high flow nasal cannula or a regular one. The trial seeks individuals planning to undergo an EBUS bronchoscopy who typically receive moderate sedation. Those with a history of nasal surgery or specific breathing issues may not be suitable candidates. As an unphased trial, this study offers a unique opportunity to contribute to advancements in lung procedure techniques.

The trial requires that you stop taking any blood thinners (anticoagulation medications) before the procedure. For other medications, the protocol does not specify, so it's best to discuss with the trial team.

Research has shown that high flow nasal cannula (HFNC) is generally safe and well-tolerated by patients. Studies have found that HFNC can improve oxygen levels and reduce the need for reintubation. It is also associated with shorter hospital stays and less dryness in the nose and mouth compared to other oxygen therapies. Importantly, HFNC does not increase the risk of lung infections or death compared to other treatments. Overall, evidence suggests that HFNC is a reliable and safe method for delivering oxygen to patients, including those with cancer.¹²³⁴⁵

Researchers are excited about high flow nasal cannula oxygen because it offers a new way to support lung cancer patients during procedures. Unlike regular nasal cannulas, which deliver oxygen at a lower flow rate, the high flow nasal cannula provides a higher oxygen concentration using a Vapotherm device. This method can enhance comfort and improve oxygen levels more efficiently, potentially leading to better outcomes and quicker recovery for patients. By delivering humidified and heated oxygen, it may also reduce airway dryness and irritation, which are common issues with standard oxygen therapy.

Research has shown that high flow nasal cannula (HFNC) therapy can effectively assist patients during breathing treatments. One study found that patients who successfully used HFNC had a 94% survival rate in the hospital, while those for whom HFNC was ineffective had a 0% survival rate. HFNC also correlates with shorter hospital stays and less discomfort, such as dryness in the nose and mouth. For cancer patients, HFNC may alleviate breathing problems and enhance quality of life. In this trial, participants will receive either HFNC or a regular nasal cannula during procedures. These findings suggest that HFNC could make procedures like bronchoscopy safer and more comfortable by reducing interruptions and instances of oxygen level drops.²³⁶⁷⁸